![]() |
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Fusion gene ID: 13024 |
FusionGeneSummary for FBLN7_ALOXE3 |
![]() |
Fusion gene information | Fusion gene name: FBLN7_ALOXE3 | Fusion gene ID: 13024 | Hgene | Tgene | Gene symbol | FBLN7 | ALOXE3 | Gene ID | 129804 | 59344 |
Gene name | fibulin 7 | arachidonate lipoxygenase 3 | |
Synonyms | TM14 | ARCI3|E-LOX|eLOX-3|eLOX3 | |
Cytomap | 2q13-q14.1 | 17p13.1 | |
Type of gene | protein-coding | protein-coding | |
Description | fibulin-7FIBL-7 | hydroperoxide isomerase ALOXE3Epidermal lipoxygenase-3e-LOX-3epidermal LOX-3epidermal lipoxygenaseepidermis-type lipoxygenase 3hydroperoxy icosatetraenoate dehydratase | |
Modification date | 20180522 | 20180519 | |
UniProtAcc | Q53RD9 | Q9BYJ1 | |
Ensembl transtripts involved in fusion gene | ENST00000331203, ENST00000409903, ENST00000409667, ENST00000409450, ENST00000472377, | ENST00000380149, ENST00000448843, ENST00000318227, | |
Fusion gene scores | * DoF score | 2 X 2 X 2=8 | 1 X 1 X 1=1 |
# samples | 2 | 1 | |
** MAII score | log2(2/8*10)=1.32192809488736 | log2(1/1*10)=3.32192809488736 | |
Context | PubMed: FBLN7 [Title/Abstract] AND ALOXE3 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | ALOXE3 | GO:0006665 | sphingolipid metabolic process | 21558561 |
Tgene | ALOXE3 | GO:0019369 | arachidonic acid metabolic process | 12881489|17045234 |
Tgene | ALOXE3 | GO:0019372 | lipoxygenase pathway | 20921226 |
Tgene | ALOXE3 | GO:0043651 | linoleic acid metabolic process | 12881489|17045234 |
Tgene | ALOXE3 | GO:0051122 | hepoxilin biosynthetic process | 12881489|17045234 |
![]() (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | LD | SARC | TCGA-DX-A6YQ-01A | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Frame-shift | ENST00000331203 | ENST00000380149 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000331203 | ENST00000448843 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000331203 | ENST00000318227 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409903 | ENST00000380149 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409903 | ENST00000448843 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409903 | ENST00000318227 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409667 | ENST00000380149 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409667 | ENST00000448843 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409667 | ENST00000318227 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409450 | ENST00000380149 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409450 | ENST00000448843 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Frame-shift | ENST00000409450 | ENST00000318227 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
intron-3CDS | ENST00000472377 | ENST00000380149 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
intron-3CDS | ENST00000472377 | ENST00000448843 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
intron-3CDS | ENST00000472377 | ENST00000318227 | FBLN7 | chr2 | 112942916 | + | ALOXE3 | chr17 | 8012572 | - |
Top |
FusionProtFeatures for FBLN7_ALOXE3 |
![]() |
Hgene | Tgene |
FBLN7 | ALOXE3 |
An adhesion molecule that interacts with extracellularmatrix molecules in developing teeth and may play important rolesin differentiation and maintenance of odontoblasts as well as indentin formation. {ECO:0000250}. | Non-heme iron-containing lipoxygenase which is atypicalin that it displays a prominent hydroperoxide isomerase activityand a reduced dioxygenase activity compared to otherlipoxygenases. The hydroperoxide isomerase activity catalyzes theisomerization of hydroperoxides, derived from arachidonic andlinoleic acid by ALOX12B, into hepoxilin-type epoxyalcohols. Thedioxygenase activity requires a step of activation of the enzymeby molecular oxygen. In presence of oxygen, oxygenatespolyunsaturated fatty acids, including arachidonic acid, toproduce fatty acid hydroperoxides. In the skin, acts downstream ofALOX12B on the linoleate moiety of esterified omega-hydroxyacyl-sphingosine (EOS) ceramides to produce an epoxy-ketone derivative,a crucial step in the conjugation of omega-hydroxyceramide tomembrane proteins. Therefore plays a crucial role in the synthesisof corneocytes lipid envelope and the establishment of the skinbarrier to water loss. In parallel, it may have a signalingfunction in barrier formation through the production of hepoxilinsmetabolites. Plays also a role in adipocyte differentiationthrough hepoxilin A3 and hepoxilin B3 production which in turnactivate PPARG. Through the production of hepoxilins in the spinalcord, it may regulate inflammatory tactile allodynia.{ECO:0000269|PubMed:12881489, ECO:0000269|PubMed:17045234,ECO:0000269|PubMed:20921226, ECO:0000269|PubMed:20923767,ECO:0000269|PubMed:21558561}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for FBLN7_ALOXE3 |
![]() (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for FBLN7_ALOXE3 |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
FBLN7 | HSPA5, ASPH, TXNDC11, CLNS1A, EDEM2, EGFR | ALOXE3 | C20orf96, ALPK1, GLIPR1, DPPA4, B3GALNT1, PLEKHB2, VEGFB, GLYR1, NBEA, ZFHX4, DNAAF2, SRC, HSPA8, CCDC27, ZSCAN12, EDEM3, MORN3, HOOK1, PVRL2, HERC4, ZIC1, HSPD1 |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for FBLN7_ALOXE3 |
![]() (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for FBLN7_ALOXE3 |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | ALOXE3 | C3539888 | ICHTHYOSIS, CONGENITAL, AUTOSOMAL RECESSIVE 3 | 4 | UNIPROT |
Tgene | ALOXE3 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Tgene | ALOXE3 | C0079154 | Congenital Nonbullous Ichthyosiform Erythroderma | 1 | CTD_human;ORPHANET |